Clinical Trials
Study Title:
A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado Trastuzumab Emtansine For Recurrent, Metastatic or Treatment Naïve, Unresectable HER-2 Positive Salivary Gland Cancer
For more information about the trial above please contact the study team:
Medical University of South Carolina Principal Investigator, John Kaczmar, at kaczmar@musc.edu, or please call +1 843-792-6691. Study Coordinator, Madison Avinger, at avingerm@musc.edu.
Trial opened at the following institutions: Medical University of South Carolina |